CPC C12Q 1/6886 (2013.01) [A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61P 35/00 (2018.01); C12N 5/0693 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/686 (2013.01); G01N 33/57434 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/166 (2013.01); G01N 2800/52 (2013.01)] | 19 Claims |
1. A method of treating prostate cancer in a subject in need thereof, comprising:
(a) comparing a protein expression level of KDM5D in a sample from the subject to a protein expression level of KDM5D in a control sample, and
(b) when the protein expression level of KDM5D in the sample from the subject is the same as or higher than the protein expression level of KDM5D in the control sample, then administering a taxane without androgen deprivation therapy (ADT) to the subject or administering ADT without a taxane,
and when the protein expression level of KDM5D in the sample from the subject is lower than the protein expression level in the control sample, administering taxane and an ADT to the subject.
|